Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Libbs Farmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Candesartan Cilexetil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Libbs Farmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hyperten...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 14, 2021
Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $400.0 million
Deal Type : Divestment
AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed
Details : AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapha...
Product Name : Atacand
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $400.0 million
Deal Type : Divestment
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $400.0 million
Deal Type : Divestment
Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries
Details : AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.
Product Name : Atacand
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2020
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $400.0 million
Deal Type : Divestment
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Candesartan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2020
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin
Details : Candesartan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2020
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable